Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$153.41 USD

153.41
3,229,121

-3.19 (-2.04%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $153.70 +0.29 (0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (69 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Henry Schein (HSIC) Q4 Earnings Miss, Operating Margin Down

by Zacks Equity Research

Henry Schein (HSIC) posts lower-than-expected earnings and revenues in the fourth quarter of 2023.

Zacks Equity Research

Best Growth Stocks to Buy for February 27th

by Zacks Equity Research

POWL, CAH and TXT made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 27, 2023.

Ethan Feller headshot

Momentum Monday: Bull Market Continues

by Ethan Feller

Want to start the week ahead of the pack? Check out Momentum Mondays

Zacks Equity Research

Here's Why You Should Buy Edward Lifesciences (EW) Stock Now

by Zacks Equity Research

Investors are optimistic about Edward Lifesciences' (EW) progress with the Structural Heart business and strong TAVR potential.

Zacks Equity Research

Penumbra (PEN) Q4 Earnings Top Estimates, Margins Increase

by Zacks Equity Research

Penumbra's (PEN) Q4 revenues register year-over-year growth driven by robust U.S. thrombectomy sales.

Zacks Equity Research

ClearPoint Neuro (CLPT) Gets FDA's Nod for New Software

by Zacks Equity Research

ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to provide fast, peri-procedural segmentation of the cortical structures of the brain.

Zacks Equity Research

Here's Why You Should Add Lantheus (LNTH) to Your Portfolio

by Zacks Equity Research

Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.

Zacks Equity Research

Bruker's (BRKR) New Launches Drive Growth Amid FX Woes

by Zacks Equity Research

Bruker's (BRKR) revenues continue to be driven by the strength of end markets, including academic and government, and industrial.

Zacks Equity Research

Philips' (PHG) New Innovation to Boost Radiation-Free Imaging

by Zacks Equity Research

Philips (PHG) announces its latest LumiGuide imaging technology, which is likely to pave the way for new radiation-free procedures. It will prove beneficial for complex aortic surgeries.

Zacks Equity Research

Here's Why Investors Should Hold Labcorp (LH) Stock for Now

by Zacks Equity Research

Targeted development in high-growth areas and strategic partnerships bode well for Labcorp (LH).

Zacks Equity Research

Charles River (CRL) Forges Collaboration With Wheeler Bio

by Zacks Equity Research

Charles River (CRL) and Wheeler Bio join forces to accelerate the journey from discovery and CMC development to manufacturing.

Zacks Equity Research

Amedisys' (AMED) Q4 Earnings Miss Estimates, Margins Up

by Zacks Equity Research

The continuous shortage of clinical labor, nursing in particular, is likely to have impacted Amedisys' (AMED) Q4 performance.

Zacks Equity Research

BD (BDX), Camtech Health Unite to Aid Cervical Cancer Screening

by Zacks Equity Research

BD (BDX) collaborates with Camtech Health to improve the rate of cervical cancer screening in Singapore by offering women an option to self-collect samples in the privacy of their own homes.

Zacks Equity Research

Lantheus (LNTH) Q4 Earnings Surpass Estimates, Gross Margin Up

by Zacks Equity Research

Lantheus' (LNTH) robust segmental revenues drive its fourth-quarter performance.

Zacks Equity Research

3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio for Now

by Zacks Equity Research

Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.

Zacks Equity Research

Teleflex (TFX) Q4 Earnings Top Estimates, Operating Margin Falls

by Zacks Equity Research

Teleflex (TFX) surpasses earnings and revenue estimates in the fourth quarter of 2023.

Zacks Equity Research

Best Growth Stocks to Buy for February 23rd

by Zacks Equity Research

CAH, POWL and PAX made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 23, 2024.

Zacks Equity Research

Best Value Stocks to Buy for February 23rd

by Zacks Equity Research

BLDR and CAH made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 23, 2024.

Zacks Equity Research

Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands

by Zacks Equity Research

Veracyte's (VCYT) fourth-quarter 2023 performance reflects solid financial discipline and the strength of the Decipher Prostate and Afirma tests.

Zacks Equity Research

Best Income Stocks to Buy for February 23rd

by Zacks Equity Research

AROC, JSAIY and CAH made it to the Zacks Rank #1 (Strong Buy) income stocks list on February 23, 2024.

Zacks Equity Research

New Strong Buy Stocks for February 23rd

by Zacks Equity Research

IRDM, JSAIY, CAH, LNTH and CENTA have been added to the Zacks Rank #1 (Strong Buy) List on February 23, 2024.

Zacks Equity Research

ICON (ICLR) Q4 Earnings Surpass Estimates, Margins Expand

by Zacks Equity Research

ICON's (ICLR) solid performance in the fourth quarter reflects continued market leadership across customer segments it serves.

Zacks Equity Research

Better Therapeutics' (BTTX) CBT Gains FDA's Breakthrough Status

by Zacks Equity Research

Better Therapeutics' (BTTX) novel CBT platform attains the FDA's breakthrough device designation to improve patient care in the treatment of liver and metabolic diseases.

Zacks Equity Research

Nevro's (NVRO) Q4 Earnings and Sales Top Estimates, Margins Up

by Zacks Equity Research

Nevro's (NVRO) fourth-quarter earnings and revenues surpass their respective consensus estimate. The company incurs a loss in the operating level.

Zacks Equity Research

Exact Sciences (EXAS) Q4 Loss Narrows, Revenues Rise Y/Y

by Zacks Equity Research

Robust revenues from Exact Sciences' (EXAS) Screening and Precision Oncology segments contribute to the fourth-quarter top line.